FDA Breakthrough Device Designation: Eligibility, Benefits, and Application Strategy

What Is FDA Breakthrough Device Designation -- and Why Should You Care?

If your medical device addresses a life-threatening or irreversibly debilitating condition and offers a meaningful advantage over existing alternatives, the FDA Breakthrough Device Program may be one of the most powerful regulatory tools available to you. Yet many device companies either do not know they qualify or submit requests that are too vague, too early, or strategically misaligned with what FDA is actually looking for.

This post breaks down the eligibility criteria, the real-world benefits, and the application strategy that separates successful requests from rejected ones -- so you can make an informed decision about whether to pursue this pathway.

The Regulatory Foundation

The Breakthrough Device Program was established under Section 515B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), added by the 21st Century Cures Act of 2016. It applies to devices subject to premarket approval (PMA), De Novo classification, or 510(k) clearance. The program is administered under FDA guidance titled 'Breakthrough Devices Program' (December 2018, updated periodically), which remains the primary reference for both eligibility interpretation and submission expectations.

This program replaced the prior Expedited Access Pathway (EAP) and incorporates lessons learned from that program's limited uptake. Understanding this lineage matters -- it tells you that FDA designed Breakthrough with a more collaborative, less burdensome interaction model in mind.

Eligibility: Two Criteria That Both Must Be Met

To qualify, a device must satisfy two distinct prongs under Section 515B(d)(1):

• Criterion 1 -- Disease or condition: The device must be intended to treat or diagnose a disease or condition that is life-threatening or irreversibly debilitating. FDA interprets this broadly but expects sponsors to substantiate the clinical seriousness of the condition with literature or epidemiological data.
• Criterion 2 -- Advantage over alternatives: The device must meet at least one of the following: it provides for more effective treatment or diagnosis than currently available alternatives; it eliminates or reduces the need to hospitalize patients; it offers management of conditions in outpatient settings where hospitalization was previously required; or it provides for the development of a device in cases where no approved alternatives exist.

A common mistake is assuming that novelty alone is sufficient. FDA is looking for a clinically meaningful advantage -- not just a technological one. Your request must clearly articulate what patients gain and why existing cleared or approved options fall short.

The Real Benefits: More Than Just Speed

The word 'expedited' often leads sponsors to focus narrowly on faster review timelines. While FDA does prioritize Breakthrough devices and commits to more interactive review, the deeper benefits are strategic:

• Early and frequent interactions with FDA: Sponsors receive priority access to agency staff for pre-submission meetings (Q-submissions under 21 CFR Part 807 and FDA's Q-Sub guidance), which means you can resolve open questions about clinical study design, software validation, or predicate selection before investing significant resources.
• Senior FDA staff involvement: FDA commits to involving senior agency staff in key interactions, which generally results in more substantive and actionable feedback.
• Flexibility in clinical study design: FDA signals openness to adaptive trial designs, surrogate endpoints, and real-world evidence where traditional RCT structures may be impractical -- particularly relevant for SaMD and AI/ML-enabled devices.
• Potential for rolling review: For PMA applicants, Breakthrough designation enables rolling submission, allowing FDA to review completed sections before the full application is submitted. This alone can compress your time to market by months.

Application Strategy: What Separates Approvals from Rejections

The Breakthrough Device request is submitted as a pre-submission (Q-Sub) and is typically reviewed within 60 days. FDA does not publicly disclose acceptance rates, but internal patterns are observable to experienced regulatory consultants.

Here is what a strong request looks like in practice:

• Lead with the patient, not the product: Open with a compelling, evidence-backed description of the disease burden and the unmet clinical need. FDA reviewers are clinically trained -- write for them, not for investors.
• Be specific about the advantage claimed: Vague statements like 'more effective' are insufficient. Quantify where possible: faster diagnosis, reduced procedural risk, elimination of a specific complication. Reference published clinical data that supports your comparator characterization.
• Define your regulatory pathway before you apply: FDA expects you to know whether you are pursuing 510(k), De Novo, or PMA. Your designation request should align your clinical evidence strategy with that pathway from the start.
• Address predicate or comparator landscape clearly: If existing devices have limitations, document them with citations. If no predicate exists, explain how that supports the 'no approved alternatives' criterion.
• Anticipate FDA questions: Include a brief outline of your proposed development plan. FDA wants to see that you are ready to use the interactive engagement opportunities that Breakthrough provides -- not just seeking a marketing label.

Is Breakthrough Right for Your Device?

Breakthrough designation is not appropriate for every novel device. If your device addresses a less serious condition, or if adequate alternatives already exist with comparable clinical performance, the designation will not be granted -- and a rejected request can consume time and resources better spent elsewhere. Conversely, if you do qualify and do not apply, you are leaving substantial regulatory capital on the table.

The decision to pursue Breakthrough should be made as part of a broader regulatory strategy -- not in isolation. It should inform your clinical trial design, your pre-submission meeting agenda, your IDE strategy if applicable, and your overall timeline to market.

Work With a Consultant Who Has Done This Before

At ADB Consulting and CRO Inc., Andre Butler and the team work directly with device startups and established manufacturers to evaluate Breakthrough eligibility, draft compelling designation requests, and structure the FDA interaction strategy that follows. We do not hand you a template -- we build a submission that reflects your specific device, your clinical evidence, and your regulatory pathway.

If you are developing a device that could change outcomes for patients with serious conditions, let us help you determine whether Breakthrough designation belongs in your strategy.

Book a free discovery call at adbccro.com and speak directly with our regulatory team. No sales pitch -- just an honest assessment of your pathway and your options.